Skip to content
Ranked #54Desk pick
Apex MD

People who want nationwide access to compounded glp-1 with unlimited visits and labs included.

semaglutide
$299/mo
tirzepatide
$399/mo
Before enrolling

Compounds bundle NAD, B-12 and L-Carnitine rather than a single-ingredient GLP-1

vs
Ranked #115
SkinnyRx

A tablet route on either molecule; anyone shopping tirzepatide month to month should compare $299/mo, not the $99 first month, and semaglutide buyers should get the renewal price in writing first.

semaglutide
$99intro + renewal; see terms
tirzepatide
$299/mo

FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.

Our review of Apex MD gives it 80/100 (B−), while our review of SkinnyRx gives it 74/100 (C). The score breakdown shows where each provider does better.

Desk Score, dimension by dimension

Same six measured dimensions for both. The green bar marks the stronger score. See the methodology.

Apex MD

80/100

B−

Overall

SkinnyRx

74/100

C

Price transparency

94
48

State access

86
86

Molecule range

77
92

Onboarding speed

65
80

Support responsiveness

77
80

Licensing & trust

69
62

The spec sheet

Check the billing terms before comparing the figures. Our guide to paying for GLP-1 care without insurance explains how medication charges, membership fees and prepaid terms affect what you owe.

FieldApex MDSkinnyRx
Semaglutide$299/mo
Full plan terms

$299/mo

$99intro + renewal; see terms
Full plan terms

$99 first month (no renewal price is printed on its public pages; compounded injection; semaglutide tablets $149 first month, also with no renewal price printed)

Tirzepatide$399/mo
Full plan terms

$399/mo

$299/mo
Full plan terms

$299/mo month-to-month (first month $99; $289/mo on 4 months, $250/mo on 6 months, $225/mo on 12 months; compounded; tablets the same after a $199 first month, with a 3-month plan in place of the 4-month one; whether longer plans are charged up front is not stated on its public pages)

CoverageAll 50 states47 states + DC (not Alabama, Louisiana or Mississippi)
Brand-nameNot confirmed hereNot confirmed here
Oral optionOral option listedOral option listed
Best forPeople who want nationwide access to compounded glp-1 with unlimited visits and labs included.A tablet route on either molecule; anyone shopping tirzepatide month to month should compare $299/mo, not the $99 first month, and semaglutide buyers should get the renewal price in writing first.
Desk Score80/100B−74/100C

The verdict

Desk pick — Apex MD

Apex MD has the higher Desk Score, but SkinnyRx may be a better fit if it covers your state, offers the prescribed product or has billing terms that work better for you.

Choose Apex MD if…

People who want nationwide access to compounded glp-1 with unlimited visits and labs included.

$299/mo sema · $399/mo tirz · All 50 states

Choose SkinnyRx if…

A tablet route on either molecule; anyone shopping tirzepatide month to month should compare $299/mo, not the $99 first month, and semaglutide buyers should get the renewal price in writing first.

$99 (intro + renewal; see terms) sema · $299/mo tirz · 47 states + DC (not Alabama, Louisiana or Mississippi)

FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.

Assume any provider we list may compensate us. We may earn a referral commission at no extra cost to you, and compensation does not change the Desk Score.

Also here

CoreAge Rx leads the whole ranking at 94/100

Whichever of these two you lean toward, our #1-rated provider outscores them both. Both compounded injections with dose-independent advertised rates. The $79 and $129 monthly equivalents require a year paid in full; confirm the total charge and refund terms.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.